Yang Hai-Chun, Fogo Agnes B
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Adv Chronic Kidney Dis. 2014 Sep;21(5):442-7. doi: 10.1053/j.ackd.2014.04.001.
It is well known that progression of chronic kidney disease can be ameliorated or stabilized by different interventions, but more studies indicate that it can even be reversed. Most data suggest that current therapy, especially renin-angiotensin system inhibition alone, is not sufficient to initiate and maintain long-term regression of glomerular structural injury. In this article, we review the potential reversal of glomerulosclerosis and evidence from both human and animal studies. We discuss mechanisms that involve matrix remodeling, capillary reorganization, and podocyte reconstitution. In the future, a multipronged strategy including novel anti-inflammatory and antifibrotic molecules should be considered to potentiate regression of glomerulosclerosis.
众所周知,慢性肾脏病的进展可通过不同干预措施得到改善或稳定,但更多研究表明其甚至可以逆转。大多数数据表明,当前的治疗方法,尤其是单独使用肾素-血管紧张素系统抑制剂,不足以启动并维持肾小球结构损伤的长期逆转。在本文中,我们回顾了肾小球硬化潜在的逆转情况以及来自人类和动物研究的证据。我们讨论了涉及基质重塑、毛细血管重组和足细胞重构的机制。未来,应考虑采用包括新型抗炎和抗纤维化分子在内的多管齐下策略,以增强肾小球硬化的逆转。